重组促红细胞生成素改善住院COVID-19患者疗效与安全性的随机对照试验方案结构化摘要
该研究为在伊朗开展的单盲、随机、安慰剂对照2期临床试验,计划纳入20例PCR确诊、Hb≤9且至少有一种重症表现的≤65岁COVID-19住院患者,按1:1随机接受标准治疗联合重组促红细胞生成素或安慰剂。主要结局为症状与实验室指标组成的复合终点,评估于基线和第5天。
要点
- 受试者为PCR确诊、Hb≤9且至少一项重症表现的≤65岁住院患者。
- 干预组接受标准治疗联合重组促红细胞生成素300 U/kg或4000 IU皮下注射,每日三次,共5天,并每日皮下注射依诺肝素1 mg/kg预防血栓。
- 主要结局为症状与实验室指标组成的复合终点,在基线和第5天评估。
核心结论
- 该方案旨在评估重组促红细胞生成素对住院COVID-19患者症状和实验室指标的改善作用及安全性。
研究设计与样本
- 隐蔽、随机、单盲、2期对照临床试验,采用两组平行设计,20例患者按1:1比例分配,对照组使用安慰剂。
- 研究在伊朗霍尔木兹甘省阿巴斯港Shahid Mohammadi医院进行,计划入组20例,干预组和对照组各10例。
- 采用置换区组随机化方法,通过在线网络工具进行随机分组。
关键数值与推荐
- 纳入标准:PCR确诊COVID-19、年龄≤65岁、Hb≤9,且至少具备以下之一:呼吸频率>30次/分、O2饱和度≤93%或动脉血氧分压比<300、24至48小时内肺部浸润>50%肺野、进行性淋巴细胞减少、LDH>245 U/I、CRP>100。
- 排除标准包括冠心病、血栓形成、深静脉血栓、慢性肺病、糖尿病、免疫系统减弱、终末期肾病、肝病、口服避孕药史、收缩压>160 mmHg、舒张压>90 mmHg、年龄>65岁及促红细胞生成素>500。
- 干预组:标准治疗联合重组促红细胞生成素(EPREX)300 U/kg或4000 IU皮下注射,每日三次,共5天,同时每日皮下注射依诺肝素1 mg/kg预防血栓。
- 对照组:标准治疗联合安慰剂(注射用无菌水)皮下注射,每日三次,共5天。
- 主要结局为复合终点,包括呼吸频率、氧饱和度、动脉血氧分压比、肺部浸润、血压、LDH、CRP、淋巴细胞计数、内源性促红细胞生成素和血红蛋白水平,在基线及干预后第5天评估。
临床怎么用
- 该方案为2期探索性试验,结果尚待报告,暂不能形成临床推荐。
局限性
- 样本量仅20例,统计效能有限。
- 采用单盲设计,主要研究者、医护人员、数据收集者和结局评估者知晓分组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effect of recombinant erythropoietin on hospitalised COVID-19 patients. TRIAL DESIGN: Concealed, randomized, single-blinded, phase 2 controlled clinical trial with two arm parallel-group design of 20 patients allocated with 1:1 ratio and using the placebo in the control group. PARTICIPANTS: This study will be performed at Shahid Mohammadi Hospital in Bandar Abbas, Hormozgan in Iran. All positive (PCR confirmed) COVID-19 patients ≤65 years old who have Hb≤9 and at least one of the severe COVID-19 symptoms (tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 ≤93 saturation, the partial pressure ratio of arterial oxygen <300), Lung infiltration (> 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100) and are willing to cooperate in this project will be included in the study. Patients with a history of coronary heart disease, thrombosis, deep vein thrombosis, chronic lung disease, diabetes mellitus, weakened immune system, end-stage renal disease, liver disease, and patients with a history of taking oral contraceptive pills, systolic blood pressure more than 160 mm Hg, diastolic blood pressure more than 90 mm Hg and age over 65 and erythropoietin above 500 are excluded. INTERVENTION AND COMPARATOR: Patients will receive the standard of care (SOC) based on the treatment protocols of the Iranian National Committee of COVID-19 and recombinant erythropoietin (EPREX Manufactured by Johnson and Johnson Pharmaceutical Company) 300 units / Kg or 4000IU as subcutaneous (SQ) injection three times a day for 5 days and simultaneously Enoxaparin 1 mg/kg SQ daily is also taken to prevent thrombosis in the intervention group. Patients' blood pressure, along with other vital signs, are checked regularly and at regular intervals. In the control group, patients received SOC and the placebo (distilled water) is given as a subcutaneous injection three times a day for 5 days. We use sterile water for injection (EXIRpharmaceutical company) as the placebo. To the same appearance of the placebo and the recombinant erythropoietin, they are taken in a separate room in the same size syringes and cover with labels before injection. MAIN OUTCOMES: The main outcome for this study is a composite endpoint for Patient clinical symptoms (Respiratory rate, Oxygen saturation state and arterial oxygen partial pressure ratio, Lung infiltration status, blood pressure), Laboratory tests (LDH, CRP, Lymphocyte count, Endogenous erythropoietin, and Haemoglobin level). All of these will be assessed at the beginning of the study (before the intervention) and day 5 after the intervention. The study will also evaluate side effects and how to manage them. RANDOMISATION: Eligible participants (20) will be randomized in two arms in the ratio of 1: 1 (10 per arm) by permuted block randomization method using online web-based tools. BLINDING (MASKING): Patients participating in the study will not be aware of the assignment to the intervention or control group. The principal investigator, health care personnel, data collectors, and those evaluating the outcome are aware of patient grouping. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 20 patients will participate in this study, who are randomly allocated to the 2 arms with a 1:1 ratio; 10 patients in the intervention group will receive SOC and recombinant erythropoietin, and 10 patients in the control group will receive SOC and placebo. TRIAL STATUS: The protocol version is 3.0, approved by the Deputy of Research and Technology and the ethics committee of Hormozgan University of Medical Sciences on 6th June 2020, with the local grant number of 990108. The expected recruitment end date was on 21th December 2020 but since we had a wide and careful exclusion criteria because of the adverse reactions of the medication, the recruitment (for both cases and controls) was not so easy and did not finish on the expected date and we are still recruiting now. Recruitment began on 17th August 2020 and the updated expected recruitment end date is 1st August 2021. TRIAL REGISTRATION: The protocol was registered before starting subject recruitment under the title: Evaluation of the effect of recombinant erythropoietin on the improvement of COVID-19 patients, IRCT20200509047364N1, at Iranian Registry of clinical trials ( https://en.irct.ir/trial/49282 ) on 2020/08/09. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
引用
- Samimagham HR, Azad MH, Hooshyar D, et al. Evaluation of the efficacy and safety of recombinant erythropoietin on the improvement of hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 34229729. doi:10.1186/s13063-021-05363-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。